Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & Aadi Bioscience (NASDAQ:AADI)

Profitability

This table compares Petros Pharmaceuticals and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Earnings and Valuation

This table compares Petros Pharmaceuticals and Aadi Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11 million	0.15	-$8.16 million	($52.91)	0.00
Aadi Bioscience	$25.07 million	1.91	-$65.76 million	($2.35)	-0.83

Petros Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Petros Pharmaceuticals has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Summary

Aadi Bioscience beats Petros Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.